Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day.

As quoted in the press release:

“The important clinical and preclinical updates we shared today further establish Abeona’s pathway to bring long-term value to our shareholders and hope to our patients,” said João Siffert, M.D., interim Chief Executive Officer, Chief Medical Officer and Head of R&D. “We are very pleased to share next steps for our lead programs and to unveil the potential of the novel AIM^TMAAV vector platform that could be a catalyst for the next generation of gene therapy.”

Click here to read the full press release.